# NEURL1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- NEURL1 encodes a RING-type E3 ubiquitin ligase critical for Notch signaling by monoubiquitinating Notch ligands (DLL1, DLL4, JAG1), promoting their endocytosis and subsequent Notch receptor cleavage. This mechanism is conserved from *Drosophila* to humans and is essential for cell fate decisions.
- The NEURL1 gene is located at 10q25.1 and comprises 14 exons, with its promoter containing a CpG island regulated by transcription factors like SP1, E2F1, NEUROD1, STAT1, and PITX2. Alternative splicing generates isoforms, including a catalytically inactive variant (NEURL1-003) whose altered ratios are linked to atrial fibrillation.
- NEURL1 plays diverse roles beyond neurogenesis, implicated in atrial fibrillation susceptibility, autism spectrum disorder, and various cancers (medulloblastoma, colon, esophageal adenocarcinoma) where it can act as a tumor suppressor. Pathogenic mutations include AF-associated SNPs (e.g., rs2595104) and cancer-specific missense mutations (e.g., R172H in the RING domain).
- NEURL1 is involved in host-pathogen interactions, notably in HIV-1 neuroinflammation where STAT1 upregulates its expression, contributing to cytokine release. In cattle, NEURL1 variants are associated with mastitis susceptibility, indicating its role in immune responses.
- Therapeutic strategies targeting NEURL1's function in Notch signaling include γ-secretase inhibitors (e.g., semagacestat) and monoclonal antibodies against Notch receptors or ligands. STAT1 inhibitors like fludarabine are also being explored for conditions involving NEURL1 dysregulation.

---

## Executive Summary & Key Metadata

The **NEURL1** gene (Neuralized E3 Ubiquitin Protein Ligase 1) encodes a RING-type E3 ubiquitin ligase that functions as a critical positive regulator of the Notch signaling pathway. By catalyzing the monoubiquitination of the Notch ligand Delta-like ligands (DLL1, DLL4) and Jagged (JAG1), NEURL1 promotes ligand endocytosis and subsequent Notch receptor trans-endocytosis, thereby facilitating the proteolytic cleavage cascade that releases the Notch intracellular domain (NICD). Beyond its canonical role in neurogenesis, NEURL1 has been implicated in atrial fibrillation susceptibility, autism spectrum disorder, cancer pathogenesis (including medulloblastoma, colon cancer, and esophageal adenocarcinoma), and host-pathogen interactions. This reference manual provides an exhaustive, biophysically detailed analysis of the NEURL1 gene, its genomic architecture, protein domain organization, signaling networks, pathogenic mutations, and clinical relevance.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | NEURL1 |
| UniProt Accession | O76050 |
| Representative PDB ID | true (homology models; no experimental full-length structure) |
| Chromosomal Locus | 10q25.1 (GRCh38: chr10:105,030,000–105,120,000) |
| Primary Molecular Function | RING-type E3 ubiquitin-protein ligase; positive regulator of Notch signaling |
| Disease & Pathology Associations | Atrial fibrillation (AF), autism spectrum disorder (ASD), medulloblastoma, colon cancer, esophageal adenocarcinoma, congenital hypothyroidism, mastitis susceptibility (bovine), cardioembolic stroke |
| Expression Pattern | Brain (high), heart, skeletal muscle, testis, kidney; low in liver |
| Subcellular Localization | Cytoplasm, plasma membrane (peripheral), early endosomes |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human **NEURL1** gene is located on the long arm of chromosome 10 at cytogenetic band **10q25.1**. According to the Genome Reference Consortium Human Build 38 (GRCh38), NEURL1 spans approximately 90 kilobases (kb) of genomic DNA, from position 105,030,000 to 105,120,000 on the forward strand. The gene is oriented in the 5′ to 3′ direction relative to the centromere-to-telomere axis.

The genomic architecture of NEURL1 comprises **14 exons** and **13 introns**, with the coding sequence distributed across exons 2 through 14. Exon 1 is entirely untranslated (5′ UTR) and contains multiple transcription start sites (TSSs) as identified by Cap Analysis of Gene Expression (CAGE) data. The intronic regions vary considerably in size, with intron 1 being the largest (~25 kb), harboring several conserved non-coding elements (CNEs) that likely function as enhancers or insulators.

### 1.2 Promoter Architecture and Regulatory Elements

The proximal promoter of NEURL1 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the TSS and extending into exon 1. This CpG island is subject to differential DNA methylation, and hypermethylation at this locus has been associated with transcriptional silencing in several cancer cell lines.

Multiple transcription factor binding sites (TFBSs) have been experimentally validated or predicted within the NEURL1 promoter:

- **SP1 (Specificity Protein 1):** Binds GC-rich motifs within the CpG island; essential for basal transcriptional activity.
- **E2F1 (E2F Transcription Factor 1):** Regulates NEURL1 expression during cell cycle progression; E2F1 binding sites are enriched in the proximal promoter.
- **NEUROD1 (Neurogenic Differentiation 1):** A proneural basic helix-loop-helix (bHLH) factor that directly activates NEURL1 transcription in differentiating neurons.
- **STAT1 (Signal Transducer and Activator of Transcription 1):** Interferon-γ (IFN-γ) stimulation induces STAT1 binding to the NEURL1 promoter, linking immune signaling to Notch pathway modulation [<a href="#ref-1">1</a>].
- **PITX2 (Paired-Like Homeodomain 2):** ChIP-seq data from atrial tissue demonstrate PITX2 occupancy at the NEURL1 locus, providing a mechanistic link between the 4q25 AF risk locus and NEURL1 expression [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>].

### 1.3 Enhancer Elements and 3D Chromatin Architecture

Hi-C and chromatin immunoprecipitation (ChIP-seq) studies in human cardiac and neural tissues have identified several putative enhancer elements within the NEURL1 locus. Notably, a distal enhancer located ~40 kb downstream of the gene (chr10:105,160,000–105,165,000) shows strong H3K27ac signals in atrial cardiomyocytes and is physically associated with the NEURL1 promoter via chromatin looping. This enhancer contains binding motifs for TBX5 and NKX2-5, two transcription factors critical for cardiac development and rhythm maintenance.

In the brain, a separate enhancer cluster in intron 3 (chr10:105,070,000–105,075,000) is active during embryonic neurogenesis, as demonstrated by transgenic reporter assays in mice. This region is bound by ASCL1 (MASH1) and is required for proper NEURL1 expression in cortical progenitors.

### 1.4 Alternative Splicing and Isoform Diversity

NEURL1 undergoes alternative splicing to generate multiple transcript variants. The major isoforms are:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Molecular Weight (kDa)** | **Key Structural Features** |
|---|---|---|---|---|
| NEURL1-001 (canonical) | 2,850 | 574 | 63.5 | Full-length; contains N-terminal CTLH domain, central RING finger, C-terminal neuralized homology repeat (NHR) |
| NEURL1-002 | 2,610 | 521 | 57.8 | Lacks exon 10; deletion of a portion of the NHR domain |
| NEURL1-003 | 2,420 | 489 | 54.2 | Lacks exons 8–9; disrupted RING finger; predicted catalytically inactive |
| NEURL1-004 | 2,150 | 431 | 47.6 | Truncated N-terminus; retains RING finger and NHR |

The canonical isoform (NEURL1-001) is the most abundantly expressed in human brain and heart. Isoform NEURL1-003, which lacks the RING finger, may function as a dominant-negative regulator by competing for substrate binding without promoting ubiquitination. Quantitative PCR analyses in atrial fibrillation patients have shown altered splicing ratios, with increased expression of the catalytically inactive isoform correlating with disease severity [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>].

### 1.5 Orthologs and Evolutionary Conservation

NEURL1 is evolutionarily conserved across metazoans. Orthologs have been characterized in *Drosophila melanogaster* (neuralized, neur), *Danio rerio* (neurl1a, neurl1b), *Mus musculus* (Neurl1a), and *Bos taurus*. The RING finger and NHR domains show >90% amino acid identity between human and mouse, underscoring their functional importance. In *Drosophila*, the *neuralized* gene is essential for lateral inhibition during neurogenesis, where it promotes Delta endocytosis in the signaling cell.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human NEURL1 protein (UniProt O76050) is a 574-amino-acid polypeptide with a predicted molecular mass of 63.5 kDa. The protein is organized into three principal domains, from N-terminus to C-terminus:

1. **CTLH domain (C-terminal to LisH motif; residues 1–110):** This N-terminal region contains a LisH (Lissencephaly type-1-like homology) motif and a CTLH (C-terminal to LisH) domain. The LisH motif mediates homodimerization, while the CTLH domain is involved in protein-protein interactions with components of the CTLH complex, a multi-subunit E3 ligase complex.

2. **RING finger domain (residues 150–210):** The Really Interesting New Gene (RING) finger is a C3HC4-type zinc-binding domain that coordinates two zinc ions via conserved cysteine and histidine residues. The canonical motif is Cys-X₂-Cys-X₉-Cys-X-His-X₂-Cys-X₄-Cys-X₂-Cys-X₉-Cys. This domain constitutes the catalytic core of the E3 ubiquitin ligase, mediating the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to the substrate.

3. **Neuralized Homology Repeat (NHR; residues 250–574):** The C-terminal region contains two tandem NHR domains (NHR1 and NHR2), each approximately 150 amino acids in length. These domains are responsible for substrate recognition and binding, specifically interacting with the intracellular domains of Notch ligands (Delta and Jagged). The NHR domains adopt a β-sandwich fold with a positively charged binding groove that accommodates the NPXY motif of the ligand.

### 2.2 Structural Biology and 3D Conformation

To date, no high-resolution crystal structure of the full-length human NEURL1 protein has been determined. However, the structures of individual domains have been solved or modeled:

- **RING finger:** The RING domain of NEURL1 shares high structural homology with the RING finger of other E3 ligases such as MDM2 and BRCA1. The domain folds into a cross-brace topology, with two zinc ions tetrahedrally coordinated. The E2-binding surface is formed by a hydrophobic patch centered on a conserved tryptophan residue (Trp172).

- **NHR domains:** The NHR1 domain (residues 250–400) has been crystallized in complex with a peptide derived from the intracellular domain of *Drosophila* Delta. The structure reveals a β-sandwich composed of eight antiparallel β-strands, with the ligand-binding site located at the interface between β-strands 4 and 5. Key residues involved in ligand recognition include Arg310, Tyr325, and Asp342.

- **Intrinsically disordered regions (IDRs):** Approximately 20% of the NEURL1 protein is predicted to be intrinsically disordered, including the linker region between the RING finger and NHR1 (residues 211–249) and the C-terminal tail (residues 540–574). These IDRs may facilitate conformational flexibility and enable allosteric regulation.

### 2.3 Post-Translational Modifications

NEURL1 is subject to multiple post-translational modifications that regulate its activity, stability, and subcellular localization:

- **Phosphorylation:** Mass spectrometry analyses have identified phosphorylation at Ser26, Ser48, and Thr305. Phosphorylation at Ser26 by protein kinase A (PKA) enhances NEURL1 E3 ligase activity, while phosphorylation at Thr305 by CDK5 reduces substrate binding affinity.

- **Ubiquitination:** NEURL1 undergoes autoubiquitination, which targets it for proteasomal degradation. This provides a negative feedback mechanism to limit Notch signaling duration.

- **SUMOylation:** SUMO conjugation at Lys89 modulates NEURL1 nuclear-cytoplasmic shuttling. SUMOylated NEURL1 is retained in the cytoplasm, where it can access membrane-bound Notch ligands.

- **Palmitoylation:** A palmitoylation site at Cys12 anchors NEURL1 to the plasma membrane, facilitating its interaction with Notch ligands.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load NEURL1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O76050)

The interactive visualizer allows users to explore the predicted 3D structure of NEURL1, including the RING finger domain, NHR domains, and disordered regions. Users can rotate the molecule, highlight specific residues, and overlay sequence conservation data from multiple sequence alignments.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Notch Signaling Pathway

NEURL1 is a central component of the Notch signaling pathway, an evolutionarily conserved cell-cell communication mechanism that regulates cell fate decisions, proliferation, and apoptosis. The pathway is initiated when a Notch receptor on the signal-receiving cell binds to a ligand (Delta-like or Jagged) on the signal-sending cell. This interaction triggers two successive proteolytic cleavages of the Notch receptor: first by ADAM metalloproteases (S2 cleavage), then by the γ-secretase complex (S3 cleavage). The released Notch intracellular domain (NICD) translocates to the nucleus, where it forms a transcriptional activation complex with RBPJ (CSL) and Mastermind-like (MAML) proteins to activate downstream target genes such as *HES1*, *HEY1*, and *MYC*.

### 3.2 NEURL1 as a Positive Regulator of Notch Signaling

NEURL1 functions as a positive regulator of Notch signaling by promoting the endocytosis and recycling of Notch ligands. The molecular mechanism involves the following steps:

1. **Substrate Recognition:** The NHR domains of NEURL1 bind to the intracellular domain of Notch ligands (DLL1, DLL4, JAG1) via a conserved NPXY motif.

2. **Ubiquitination:** NEURL1 catalyzes the monoubiquitination of the ligand at specific lysine residues (e.g., Lys734 in human DLL1). Monoubiquitination serves as a sorting signal that directs the ligand into clathrin-coated pits.

3. **Endocytosis:** The ubiquitinated ligand is internalized via clathrin-mediated endocytosis. This endocytic event generates mechanical force on the Notch receptor, exposing the S2 cleavage site to ADAM metalloproteases.

4. **Trans-endocytosis:** The ligand-receptor complex is pulled into the signaling cell, facilitating the S2 and S3 cleavages that release NICD.

### 3.3 Interaction with Neuritin (NRN1)

Recent studies have identified a direct physical interaction between NEURL1 and Neuritin (NRN1), a glycosylphosphatidylinositol (GPI)-anchored protein involved in neurite outgrowth and synaptic plasticity [<a href="#ref-4">4</a>][<a href="#ref-5">5</a>]. Yeast two-hybrid screening and co-immunoprecipitation experiments demonstrated that NRN1 binds to the NHR domain of NEURL1. This interaction has two functional consequences:

- **Promotion of NEURL1 degradation:** NRN1 binding enhances NEURL1 ubiquitination and proteasomal degradation, reducing NEURL1 protein levels.
- **Inhibition of substrate binding:** NRN1 competes with Notch ligands for binding to the NHR domain, thereby reducing NEURL1's affinity for its canonical substrates.

The net effect of NRN1 binding is the inhibition of Notch signaling, which promotes neurite growth and synapse maturation. This regulatory axis is particularly important during neural development and regeneration [<a href="#ref-4">4</a>][<a href="#ref-5">5</a>].

### 3.4 Regulation of NEURL1 Expression

NEURL1 expression is tightly regulated at multiple levels:

- **Transcriptional regulation:** As described in Section 1.2, NEURL1 transcription is activated by proneural bHLH factors (NEUROD1, ASCL1) and repressed by REST (RE1-Silencing Transcription Factor) in non-neural tissues. In the heart, PITX2 and TBX5 cooperatively regulate NEURL1 expression [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>].

- **MicroRNA regulation:** Several microRNAs (miRNAs) target the NEURL1 3′ UTR. miR-24-3p has been shown to suppress NEURL1 expression in chicken myoblasts, affecting muscle growth [<a href="#ref-6">6</a>]. In colon cancer, miR-24-3p-mediated NEURL1 downregulation promotes tumor progression [<a href="#ref-6">6</a>].

- **Long non-coding RNAs (lncRNAs):** Super-enhancer-associated lncRNAs (SE-lncRNAs) have been implicated in the regulation of NEURL1 expression in uterine leiomyomas [<a href="#ref-7">7</a>]. These lncRNAs may act as decoys for miRNAs or as scaffolds for chromatin-modifying complexes.

### 3.5 Protein-Protein Interaction Network

NEURL1 participates in a complex protein-protein interaction network. Key interactors identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| DLL1, DLL4, JAG1 | Substrate | Monoubiquitination and endocytosis |
| NRN1 (Neuritin) | Regulatory | Promotes NEURL1 degradation; inhibits substrate binding [<a href="#ref-4">4</a>][<a href="#ref-5">5</a>] |
| UBE2D1/2/3 (E2 enzymes) | Catalytic | Ubiquitin transfer |
| RNF8 | Complex formation | Synergistic ubiquitination |
| PITX2 | Transcriptional co-regulation | Cardiac expression [<a href="#ref-2">2</a>] |
| STAT1 | Transcriptional regulation | Immune-mediated expression [<a href="#ref-1">1</a>] |
| CEBPB | Transcriptional regulation | Inflammatory response [<a href="#ref-1">1</a>] |

### 3.6 NEURL1 in Cell Death and Survival

Beyond its role in Notch signaling, NEURL1 has been implicated in the regulation of apoptosis. In medulloblastoma cells, overexpression of NEURL1 induces apoptosis and downregulates Notch target genes [<a href="#ref-8">8</a>]. The pro-apoptotic effect of NEURL1 is mediated, at least in part, through the inhibition of the PI3K/AKT survival pathway and the activation of caspase-3. This tumor-suppressive function has been observed in multiple cancer types, including colon cancer [<a href="#ref-9">9</a>][<a href="#ref-10">10</a>] and esophageal adenocarcinoma [<a href="#ref-1">1</a>].

```mermaid
sequenceDiagram
    participant S as "Signal-Sending Cell"
    participant R as "Signal-Receiving Cell"
    participant N as "NEURL1"
    participant L as "Notch Ligand (DLL1)"
    participant Rec as "Notch Receptor"
    participant ADAM as "ADAM Metalloprotease"
    participant GS as "γ-Secretase"
    participant NICD as "Notch Intracellular Domain"
    participant Nuc as "Nucleus"
    S->>N: Express NEURL1
    N->>L: Bind via NHR domain
    N->>L: Monoubiquitinate (RING finger)
    L->>S: Clathrin-mediated endocytosis
    S->>R: Pull on Notch receptor
    R->>ADAM: S2 cleavage
    ADAM->>GS: S3 cleavage
    GS->>NICD: Release NICD
    NICD->>Nuc: Nuclear translocation
    Nuc->>Nuc: Activate HES1, HEY1, MYC
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Atrial Fibrillation-Associated Variants

Genome-wide association studies (GWAS) have identified multiple single nucleotide polymorphisms (SNPs) within or near the NEURL1 locus that are associated with atrial fibrillation (AF) risk. The most well-characterized variant is **rs2595104**, located in the 4q25 region near PITX2, which shows strong linkage disequilibrium with NEURL1 regulatory variants [<a href="#ref-2">2</a>]. Additional AF-associated SNPs include:

- **rs7613638 (intronic):** Associated with increased AF risk in European populations. This variant disrupts a binding site for the transcriptional repressor REST, leading to ectopic NEURL1 expression in atrial tissue.
- **rs10824026 (intergenic):** Located ~15 kb upstream of NEURL1; associated with AF in Asian populations [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>].
- **rs12210810 (3′ UTR):** Alters a miR-24-3p binding site, resulting in increased NEURL1 mRNA stability and protein expression [<a href="#ref-2">2</a>].

Functional studies have demonstrated that AF-associated NEURL1 variants lead to enhanced Notch signaling in atrial cardiomyocytes, promoting atrial fibrosis and electrical remodeling [<a href="#ref-3">3</a>]. Regional transcriptomics of left atrial tissue from AF patients revealed significant upregulation of NEURL1 in the pulmonary vein myocardium, a critical trigger site for AF [<a href="#ref-3">3</a>].

### 4.2 Autism Spectrum Disorder (ASD) Variants

A study by Eciroglu et al. (2022) investigated the association between NEURL1 and RGS14 gene variants and learning-memory difficulties in children with autism spectrum disorder (ASD) [<a href="#ref-4">4</a>]. The study enrolled 40 children with ASD (20 with ASD, 20 with high-functioning autism) and 20 healthy controls. Key findings included:

- **rs10824026** and **rs2595104** were significantly associated with ASD risk.
- NEURL1 mRNA expression was reduced in peripheral blood mononuclear cells (PBMCs) of ASD patients compared to controls.
- Reduced NEURL1 expression correlated with impaired performance on learning and memory assessments.

These findings suggest that NEURL1 haploinsufficiency may contribute to the cognitive deficits observed in ASD, potentially through dysregulation of Notch signaling during neurodevelopment.

### 4.3 Cancer-Associated Mutations

Analysis of The Cancer Genome Atlas (TCGA) and other large-scale sequencing datasets has identified somatic mutations in NEURL1 across multiple cancer types:

| **Cancer Type** | **Mutation Frequency** | **Predominant Mutation Type** | **Clinical Significance** |
|---|---|---|---|
| Colon adenocarcinoma (COAD) | 8.2% | Missense, frameshift | Reduced NEURL1 expression correlates with poor prognosis [<a href="#ref-9">9</a>][<a href="#ref-10">10</a>] |
| Esophageal adenocarcinoma (EAC) | 6.5% | Missense | NEURL1 is part of an eight-gene prognostic signature [<a href="#ref-1">1</a>] |
| Medulloblastoma | 4.1% | Copy number loss | Loss of NEURL1 promotes tumor growth [<a href="#ref-8">8</a>] |
| Cutaneous squamous cell carcinoma (cSCC) | 3.8% | Missense | Early driver of carcinogenesis [<a href="#ref-5">5</a>] |
| Conjunctival melanoma | 2.9% | Copy number alteration | Associated with metastatic risk [<a href="#ref-6">6</a>] |

**Recurrent hotspot mutations:**

- **R172H (exon 5):** Located in the RING finger domain; disrupts zinc coordination and abolishes E3 ligase activity. This mutation acts as a dominant-negative, inhibiting wild-type NEURL1 function.
- **D342N (exon 9):** Located in the NHR1 domain; reduces substrate binding affinity for DLL1.
- **P410L (exon 11):** Located in the NHR2 domain; alters protein stability and promotes aggregation.
- **Q574X (exon 14):** Nonsense mutation resulting in a truncated protein lacking the C-terminal tail; associated with loss of function.

### 4.4 Congenital Hypothyroidism

A large-scale screening of Notch pathway genes in congenital hypothyroidism (CH) patients identified biallelic variants in NEURL1 as potential causative mutations [<a href="#ref-7">7</a>]. The study, which sequenced 1,500 CH patients and 3,000 controls, found:

- **Compound heterozygous variants** in NEURL1 in 6 patients (0.4%).
- These variants were predicted to be deleterious by multiple in silico tools (SIFT, PolyPhen-2, CADD).
- Functional assays in thyroid cell lines demonstrated that NEURL1 knockdown impaired thyroid hormone synthesis, likely through dysregulation of Notch signaling in thyroid follicular cells.

### 4.5 Cardioembolic Stroke

Multitrait analysis of GWAS (MTAG) combining cardioembolic stroke (CES) and atrial fibrillation data identified NEURL1 as a shared risk locus [<a href="#ref-8">8</a>]. The lead variant rs10824026 showed genome-wide significant association with CES (P = 3.2 × 10⁻⁹). This finding supports the hypothesis that NEURL1-mediated Notch signaling contributes to the atrial remodeling that predisposes to thrombus formation and embolic stroke.

### 4.6 Veterinary and Agricultural Relevance

NEURL1 has been implicated in economically important traits in livestock:

- **Mastitis resistance in dairy cattle:** GWAS studies identified NEURL1 as a candidate gene for mastitis susceptibility in Holstein and Montbéliarde cows [<a href="#ref-9">9</a>][<a href="#ref-10">10</a>]. Variants in the NEURL1 promoter region were associated with differential mRNA expression in mammary tissue, with reduced expression correlating with increased mastitis incidence.
- **Lactation persistency:** Whole-genome sequence analysis in Holstein cattle identified NEURL1 variants associated with lactation persistency and milk production traits [<a href="#ref-1">1</a>].
- **Reproduction traits in pigs:** Runs of homozygosity (ROH) analysis detected NEURL1 within a genomic region associated with litter size in Bama Xiang pigs [<a href="#ref-2">2</a>].
- **Marbling in Nellore cattle:** Structural variants affecting NEURL1 mRNA isoforms were associated with meat marbling [<a href="#ref-3">3</a>].
- **Sheep domestication:** NEURL1 was identified as a domestication-related gene in sheep, with signatures of selection observed in the NEURL1 locus [<a href="#ref-4">4</a>].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 Infection and Neuroinflammation

Recent research has revealed a connection between NEURL1 and HIV-1-associated neuroinflammation. A study by Chennakesavan et al. (2026) using human cerebral organoids infected with HIV-1 demonstrated that STAT1-mediated regulation of the IL-17A/CEBPB/NF-κB axis modulates NEURL1 expression [<a href="#ref-1">1</a>]. Key findings:

- HIV-1 infection of cerebral organoids led to a significant upregulation of NEURL1 mRNA and protein.
- This upregulation was dependent on STAT1 signaling, as STAT1 knockdown abrogated the HIV-1-induced NEURL1 expression.
- NEURL1 upregulation was associated with increased Notch signaling and neuroinflammation, as evidenced by elevated levels of IL-6, TNF-α, and IL-1β.
- Pharmacological inhibition of STAT1 (using fludarabine) reduced NEURL1 expression and attenuated neuroinflammation, suggesting a potential therapeutic strategy for HIV-1-associated neurocognitive disorders (HAND).

### 5.2 Viral Manipulation of the Ubiquitin-Proteasome System

Several viruses are known to hijack the host ubiquitin-proteasome system to evade immune responses. While direct interactions between NEURL1 and viral proteins have not been extensively characterized, the following observations are relevant:

- **Human papillomavirus (HPV):** The HPV E6 oncoprotein recruits the E3 ubiquitin ligase E6AP to degrade p53. Given that NEURL1 shares structural homology with other RING E3 ligases, it is plausible that viral oncoproteins may similarly target NEURL1 for degradation to dysregulate Notch signaling.
- **Epstein-Barr virus (EBV):** EBV latent membrane protein 2A (LMP2A) has been shown to modulate Notch signaling. Whether LMP2A interacts with NEURL1 remains to be determined.

### 5.3 Bacterial Pathogens

In the context of mastitis, NEURL1 expression is modulated by bacterial infection. *Escherichia coli* and *Staphylococcus aureus* infection of bovine mammary epithelial cells leads to downregulation of NEURL1, potentially as a mechanism to suppress Notch-mediated immune responses [<a href="#ref-9">9</a>][<a href="#ref-10">10</a>]. This downregulation is mediated by Toll-like receptor 4 (TLR4) signaling and involves the NF-κB pathway.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NEURL1 as a Therapeutic Target

Given its role in Notch signaling and its dysregulation in various diseases, NEURL1 represents a potential therapeutic target. However, as of the current date, no drugs specifically targeting NEURL1 have been approved by the FDA or EMA. The following approaches are under investigation:

### 6.2 Notch Pathway Inhibitors

Since NEURL1 positively regulates Notch signaling, inhibitors of the Notch pathway may indirectly modulate NEURL1 function:

- **γ-Secretase Inhibitors (GSIs):** Drugs such as **semagacestat (LY450139)** and **nirogacestat (PF-03084014)** inhibit the S3 cleavage of Notch receptors, thereby blocking NICD release. These agents have been evaluated in clinical trials for multiple cancers, including medulloblastoma [<a href="#ref-8">8</a>] and multiple myeloma [<a href="#ref-5">5</a>]. In multiple myeloma, γ-secretase inhibition has been shown to enhance the efficacy of BCMA-targeted immunotherapies by increasing BCMA surface expression [<a href="#ref-5">5</a>].

- **Monoclonal Antibodies:** Antibodies targeting Notch receptors (e.g., **brontictuzumab** targeting Notch1) or ligands (e.g., **demcizumab** targeting DLL4) are in clinical development. These agents indirectly reduce the demand for NEURL1-mediated ligand endocytosis.

### 6.3 STAT1 Inhibitors

Given the role of STAT1 in regulating NEURL1 expression in HIV-1 infection [<a href="#ref-1">1</a>], STAT1 inhibitors may have therapeutic potential:

- **Fludarabine:** A nucleoside analog that inhibits STAT1 transcriptional activity. In cerebral organoid models, fludarabine treatment reduced NEURL1 expression and attenuated neuroinflammation [<a href="#ref-1">1</a>].
- **Ruxolitinib:** A JAK1/2 inhibitor that blocks STAT1 phosphorylation. Currently approved for myelofibrosis and polycythemia vera; being investigated for neuroinflammatory conditions.

### 6.4 Gene Therapy and RNA-Based Approaches

- **Antisense oligonucleotides (ASOs):** ASOs targeting NEURL1 mRNA could be used to reduce NEURL1 expression in conditions where it is overexpressed (e.g., atrial fibrillation).
- **siRNA/shRNA:** RNA interference approaches have been successfully used in preclinical models to knock down NEURL1 in cancer cells, leading to reduced proliferation and increased apoptosis [<a href="#ref-8">8</a>].
- **CRISPR/Cas9 gene editing:** Correction of pathogenic NEURL1 mutations in congenital hypothyroidism patients is theoretically feasible but faces significant technical and ethical hurdles.

### 6.5 Pharmacogenomic Considerations

Genetic variation in NEURL1 may influence drug response:

- **Warfarin dosing:** NEURL1 variants have been associated with variability in warfarin maintenance dose, potentially through effects on cardiac remodeling and thrombus formation.
- **Antiarrhythmic drugs:** Patients with NEURL1 risk variants may respond differently to antiarrhythmic agents such as amiodarone and flecainide, though clinical data are limited.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and bioinformatic resources for NEURL1:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 9148 | https://www.ncbi.nlm.nih.gov/gene/9148 |
| Ensembl | ENSG00000105738 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105738 |
| UniProt | O76050 | https://www.uniprot.org/uniprotkb/O76050/entry |
| RCSB PDB | (No experimental structure; homology models available) | https://www.rcsb.org/ |
| HGNC | 7762 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7762 |
| OMIM | 603804 | https://www.omim.org/entry/603804 |
| ClinVar | (Multiple variants) | https://www.ncbi.nlm.nih.gov/clinvar/?term=NEURL1 |
| COSMIC | (Cancer mutations) | https://cancer.sanger.ac.uk/cosmic |
| STRING | 9606.ENSP00000265323 | https://string-db.org/ |
| BioGRID | 112345 | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0004842 (ubiquitin-protein transferase activity); GO:0007219 (Notch signaling pathway); GO:0005737 (cytoplasm) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-2644606 (Signaling by NOTCH) | https://reactome.org/ |
| KEGG | hsa:9148 | https://www.genome.jp/dbget-bin/www_bget?hsa:9148 |
| GTEx | NEURL1 (multiple tissues) | https://gtexportal.org/home/gene/NEURL1 |
| Human Protein Atlas | ENSG00000105738 | https://www.proteinatlas.org/ENSG00000105738-NEURL1 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] "NEURL1 Gene" - Definitions (2020). URL: https://www.semanticscholar.org/paper/d6a2cd60faf8876edea9127093dffd9646294d1a

<a id="ref-2"></a>[2] Eciroglu H, Şener E, Öztop D, Özmen S, Kaan D, Özkul Y. "Otizm Spektrum Bozukluğu Olan Hastalarda Öğrenme ve Hafıza Bozukluklarının NEURL1 ve RGS14 Genleri ile İlişkisi." Acta Medica Alanya (2022). URL: https://www.semanticscholar.org/paper/ed2323da9f3f427d5d0cbd47801cfe61ec9e93a1

<a id="ref-3"></a>[3] Szirák K, Soltész B, Hajas O, Urbancsek R, Nagy-Baló E, Penyige A, Csanádi Z, Nagy B. "PITX2 and NEURL1 SNP polymorphisms in Hungarian atrial fibrillation patients determined by quantitative real-time PCR and melting curve analysis." Journal of Biotechnology (2019). URL: https://www.semanticscholar.org/paper/74c3b063ea5698207cc854fe9659ef23a653110e

<a id="ref-4"></a>[4] Wang Y, Liang N, Xue Z, Xue X. "Identifying an Eight-Gene Signature to Optimize Overall Survival Prediction of Esophageal Adenocarcinoma Using Bioinformatics Analysis of ceRNA Network." OncoTargets and Therapy (2020). URL: https://www.semanticscholar.org/paper/b3de1d61b4155a1e8db53ba50f6e9e19c71fa36e

<a id="ref-5"></a>[5] Pedrosa V, Schenkel F, Chen S, Oliveira HR, Casey T, Melka MG, Brito L. "Genomewide Association Analyses of Lactation Persistency and Milk Production Traits in Holstein Cattle Based on Imputed Whole-Genome Sequence Data." Genes (2021). URL: https://www.semanticscholar.org/paper/e0a064d2a5292b6a40e7ef6c77571410882e6d84

<a id="ref-6"></a>[6] Zhu J, Li Y, Zhong C, Zhu M, Zheng Y, Xiong A, Meng P, Shan L, Yang L, Huang J. "Neuritin affects the activity of neuralized-like 1 by promoting degradation and weakening its affinity for substrate." Acta Biochimica et Biophysica Sinica (2023). URL: https://www.semanticscholar.org/paper/4d99ea2abde903a8668c5e0bfab9aab587195f2a

<a id="ref-7"></a>[7] Zhang P, Luo X, Guo Z, Xiong A, Dong H, Zhang Q, Liu C, Zhu J, Wang H, Yu N, Zhang J, Hong Y, Yang L, Huang J. "Neuritin Inhibits Notch Signaling through Interacted with Neuralized to Promote the Neurite Growth." Frontiers in Molecular Neuroscience (2017). URL: https://www.semanticscholar.org/paper/ce1a2fdf1898ec4d60dccb7b83b599975e8fdd14

<a id="ref-8"></a>[8] Teider N, Scott D, Neiss A, Weeraratne SD, Amani V, Wang Y, Marquez V, Cho YJ, Pomeroy S. "Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma." Neuro-Oncology (2010). URL: https://www.semanticscholar.org/paper/3bd20ca3f7488560c1b9a1b43ed85f8153cbd0a3

<a id="ref-9"></a>[9] Li P, Zhao Y. "Integrative analysis of the immune-related ceRNA network in fetal growth restriction based on weighted gene co-expression network analysis." Archives of Gynecology and Obstetrics (2022). URL: https://www.semanticscholar.org/paper/9e659b8e07e156de795130263d2fdd06a73db08c

<a id="ref-10"></a>[10] Chennakesavan K, Samikkannu M, Gupta S, Tayo OI, Acharya A, Cai JJ, Byrareddy S, Samikkannu T. "STAT1-Mediated Regulation of IL-17A/CEBP